Seabelife Biotech

Seabelife Biotech company information, Employees & Contact Information

We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.

Company Details

Employees
13
Founded
-
Address
Place Georges Teissier, Roscoff,29680,france
Phone
+33(0)2 98 29 23 48
Email
co****@****ife.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Roscoff
Looking for a particular Seabelife Biotech employee's phone or email?

Seabelife Biotech Questions

News

French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis - EU-Startups

French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis EU-Startups

French biotech SeaBeLife raises €2M to treat liver and eye diseases - Tech.eu

French biotech SeaBeLife raises €2M to treat liver and eye diseases Tech.eu

SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel - Ophthalmology Times Europe

SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel Ophthalmology Times Europe

French biotech SeaBeLife snaps €2M to launch clinical trials in dry AMD and acute hepatitis - Tech Funding News

French biotech SeaBeLife snaps €2M to launch clinical trials in dry AMD and acute hepatitis Tech Funding News

SeaBeLife: €2 Million Pre-Series A Secured To Advance Clinical Trials In Dry AMD And Severe Acute Hepatitis - Pulse 2.0

SeaBeLife: €2 Million Pre-Series A Secured To Advance Clinical Trials In Dry AMD And Severe Acute Hepatitis Pulse 2.0

SeaBeLife Secures €2M to Advance Cell Death-Blocking Drug Candidates - eurekamagazine.co.uk

SeaBeLife Secures €2M to Advance Cell Death-Blocking Drug Candidates eurekamagazine.co.uk

Fighting Programmed Cell Death - CHEManager

Fighting Programmed Cell Death CHEManager

SeaBeLife Gains €2 Million to Propel Drug Development - cointurk finance

SeaBeLife Gains €2 Million to Propel Drug Development cointurk finance

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant